A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
AstraZeneca
OHSU Knight Cancer Institute
Syndax Pharmaceuticals
Columbia University
Columbia University
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)